Criterion | MPR-PMR Study | The PMR Cohort |
---|---|---|
Study type | Prospective, observational | Prospective, observational |
Setting | Tertiary referral center | Primary care |
Mode of survey distribution | Clinician administered | |
Sample size, n | 37 | 652 |
Mean age, yrs ± SD | 62.9 ± 24.6 | 72.4 ± 9.3 |
Female | 46.0% | 62.2% |
White | 97.3% | 97.0% |
Diagnostic criteria | 2012 EULAR/ACR11 | Clinician diagnosis |
Treatment | BSR guideline12 | Clinician discretion |
Visit schedule | Weeks 0, 4, 8, 16, 24, 32, and 46 | Mos 0, 1, 4, 8, 12, 18, and 24 |
Followup duration | 46 weeks | 24 mos |
Instrument used to measure pain | VAS | NRS |
Pain VAS/NRS stem and anchors | Please indicate on the scale below the severity of your current muscle/joint pain (where 0 is “no pain” and 10 is “pain as bad as it could be”). | How would you rate the overall level of pain from your PMR on a 0–10 scale, where 0 is “no pain” and 10 is “pain as bad as it could be”? |
Instrument used to measure stiffness | Duration of morning stiffness, min | NRS |
Instrument used to measure physical function | HAQ-DI | MHAQ |
PMR: polymyalgia rheumatica; MPR-PMR: Melbourne Predictors of Relapse–Polymyalgia Rheumatica; MPRPMR: Melbourne Predictors of Relapse–PMR; EULAR/ACR: European ; EULAR/ACR: European League Against Rheumatism/American College of Rheumatology; BSR: British Society of Rheumatology; VAS: visual analog scale; NRS: numerical rating scale; HAQ-DI: Health Assessment Questionnaire–Disability Index; MHAQ: modified Health Assessment Questionnaire.